Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia.

Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13768-73. Epub 2007 Aug 16.

2.

No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice.

Torzewski M, Reifenberg K, Cheng F, Wiese E, Küpper I, Crain J, Lackner KJ, Bhakdi S.

Thromb Haemost. 2008 Jan;99(1):196-201. doi: 10.1160/TH07-10-0595.

PMID:
18217154
3.

Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia.

Heinonen SE, Leppänen P, Kholová I, Lumivuori H, Häkkinen SK, Bosch F, Laakso M, Ylä-Herttuala S.

Circ Res. 2007 Nov 9;101(10):1058-67. Epub 2007 Sep 13.

PMID:
17872464
4.

No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.

Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1635-40. Epub 2005 May 26.

PMID:
15920036
5.

Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?

Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1641-6. Epub 2005 May 26.

PMID:
15920030
6.

Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice.

Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA, Galle J.

Circulation. 2005 Aug 16;112(7):1016-23. Epub 2005 Aug 8.

PMID:
16087790
7.

Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice.

Ortiz MA, Campana GL, Woods JR, Boguslawski G, Sosa MJ, Walker CL, Labarrere CA.

Exp Biol Med (Maywood). 2009 Jun;234(6):624-31. doi: 10.3181/0812-RM-347. Epub 2009 Apr 9.

PMID:
19359657
9.

Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway.

Recinos A 3rd, Carr BK, Bartos DB, Boldogh I, Carmical JR, Belalcazar LM, Brasier AR.

Physiol Genomics. 2004 Sep 16;19(1):131-42. Epub 2004 Jul 6.

PMID:
15238619
10.

Uremia-specific effects in the arterial media during development of uremic atherosclerosis in apolipoprotein E-deficient mice.

Bro S, Borup R, Andersen CB, Moeller F, Olgaard K, Nielsen LB.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):570-5. Epub 2005 Dec 22.

PMID:
16373611
11.

Intrauterine exposure to maternal atherosclerotic risk factors increases the susceptibility to atherosclerosis in adult life.

Alkemade FE, Gittenberger-de Groot AC, Schiel AE, VanMunsteren JC, Hogers B, van Vliet LS, Poelmann RE, Havekes LM, Willems van Dijk K, DeRuiter MC.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2228-35. Epub 2007 Jul 26.

PMID:
17656671
12.

No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice.

Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ.

J Biol Chem. 2011 Feb 25;286(8):6272-9. doi: 10.1074/jbc.M110.161414. Epub 2010 Dec 11.

13.

The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.

Eto H, Miyata M, Shirasawa T, Akasaki Y, Hamada N, Nagaki A, Orihara K, Biro S, Tei C.

Hypertens Res. 2008 Aug;31(8):1631-42. doi: 10.1291/hypres.31.1631.

PMID:
18971539
14.

MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse.

Wågsäter D, Zhu C, Björkegren J, Skogsberg J, Eriksson P.

Int J Mol Med. 2011 Aug;28(2):247-53. doi: 10.3892/ijmm.2011.693. Epub 2011 May 6.

PMID:
21567073
15.

Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice.

Desai A, Zhao Y, Warren JS.

Cardiovasc Pathol. 2008 Jul-Aug;17(4):233-40. doi: 10.1016/j.carpath.2007.10.002. Epub 2007 Dec 3.

PMID:
18402814
16.

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8309-14. Epub 2005 May 26.

17.

Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL.

Circulation. 2009 Aug 25;120(8):699-708. doi: 10.1161/CIRCULATIONAHA.108.806547. Epub 2009 Aug 10.

PMID:
19667236
18.

Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice.

Westerterp M, Berbée JF, Pires NM, van Mierlo GJ, Kleemann R, Romijn JA, Havekes LM, Rensen PC.

Circulation. 2007 Nov 6;116(19):2173-81. Epub 2007 Oct 22.

PMID:
17967778
19.

Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice.

Matthijsen RA, de Winther MP, Kuipers D, van der Made I, Weber C, Herias MV, Gijbels MJ, Buurman WA.

Circulation. 2009 Apr 28;119(16):2188-95. doi: 10.1161/CIRCULATIONAHA.108.830661. Epub 2009 Apr 20.

PMID:
19380618
20.

Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.

Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF.

Circulation. 2007 Sep 18;116(12):1404-12. Epub 2007 Aug 27.

PMID:
17724261

Supplemental Content

Support Center